Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
Gutiérrez-Valencia A, Viciana P, Palacios R, Ruiz-Valderas R, Lozano F, Terrón A, Rivero A, López-Cortés LF; Sociedad Andaluza de Enfermedades Infecciosas. Gutiérrez-Valencia A, et al. Ann Intern Med. 2009 Aug 4;151(3):149-56. doi: 10.7326/0003-4819-151-3-200908040-00127. Epub 2009 Jul 6. Ann Intern Med. 2009. PMID: 19581631 Free article. Clinical Trial.
Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
Gutierrez-Valencia A, Chacón-Mora N, Ruiz-Valderas R, Ben-Marzouk-Hidalgo OJ, Torres-Cornejo A, Viciana P, Lopez-Cortes LF. Gutierrez-Valencia A, et al. Among authors: ruiz valderas r. Medicine (Baltimore). 2015 Oct;94(43):e1743. doi: 10.1097/MD.0000000000001743. Medicine (Baltimore). 2015. PMID: 26512567 Free PMC article.
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R. Lopez-Cortes LF, et al. J Antimicrob Chemother. 2006 Nov;58(5):1017-23. doi: 10.1093/jac/dkl357. Epub 2006 Sep 6. J Antimicrob Chemother. 2006. PMID: 16956905 Clinical Trial.
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M. Marin-Niebla A, et al. Antimicrob Agents Chemother. 2007 Jun;51(6):2035-42. doi: 10.1128/AAC.01136-06. Epub 2007 Mar 19. Antimicrob Agents Chemother. 2007. PMID: 17371813 Free PMC article. Clinical Trial.
Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.
López-Cortés LF, Viciana P, Ruiz-Valderas R, Pasquau J, Ruiz J, Lozano F, Merino D, Vergara A, Terrón A, González L, Rivero A, Muñoz-Sanz A. López-Cortés LF, et al. AIDS Res Ther. 2010 Mar 17;7:5. doi: 10.1186/1742-6405-7-5. AIDS Res Ther. 2010. PMID: 20236544 Free PMC article.
Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.
López-Cortés LF, Ruiz-Valderas R, Jimenez-Jimenez L, González-Escribano MF, Torres-Cornejo A, Mata R, Rivero A, Pineda JA, Marquez-Solero M, Viciana P; Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas. López-Cortés LF, et al. PLoS One. 2012;7(1):e28115. doi: 10.1371/journal.pone.0028115. Epub 2012 Jan 3. PLoS One. 2012. PMID: 22235243 Free PMC article. Clinical Trial.
30 results